Peptara LabsPEPTARA LABS
Back to all articles

Practical / Beginner

What I Tell Patients Before Their First Peptide Protocol

Dr. C. Lavilla, MD
By Dr. C. Lavilla, MD · 9-minute read

The conversation I have before someone starts their first peptide protocol usually takes longer than they expect. That's on purpose. What you understand before you begin shapes almost everything about how the next few months feel.

The expectations talk comes first

Most people who sit across from me have already read something online. They've seen the before-and-after photos, the confident testimonials, the promise that this time will be different. So the first thing I do is slow all of that down.

Here is what I want you to hold onto. The GLP-1 medications, the class most first-timers ask about, are real and the evidence behind them is strong. In SURMOUNT-1, published in the New England Journal of Medicine, participants on tirzepatide lost a meaningful share of their body weight over roughly 72 weeks. STEP 1, another large trial, showed similar results for semaglutide. These are not marketing numbers. They came from careful, controlled research.

But averages hide a lot. In those same trials, some people responded strongly and others barely moved. I've seen the full range in my own practice. So when someone tells me they expect to lose a specific number of kilos by a specific date, I gently pull that back. Your body is not a trial average. It has its own history, its own metabolism, its own set of reasons for holding weight.

I also tell people this early: these medications work while you take them, and the effect softens when you stop. The STEP 1 extension study followed people after they came off semaglutide, and a good portion of the lost weight returned over the following year. SURMOUNT-4 showed the same pattern after tirzepatide withdrawal. That's not a failure of the drug or of you. It's biology. Your appetite signaling shifts back. I'd rather you know that on day one than feel blindsided in month twelve.

The screening questions that actually matter

When I screen someone, I'm not just ticking boxes. I'm trying to picture how your particular body will meet this medication.

I ask about your full medical history, including thyroid conditions, pancreatitis, gallbladder problems, and any personal or family history of certain endocrine tumors. I ask what else you take, because delayed gastric emptying from GLP-1 medications can change how other oral drugs are absorbed. A 2024 paper in Drug Safety by Calvarysky and colleagues walked through exactly these kinds of interactions, and it's one of the reasons I want a complete medication list, not a partial one.

I ask about your relationship with food and your history with eating. I ask about pregnancy plans, because this matters and it's not a conversation to skip. I ask what your mental health looks like right now, and whether you've had periods where eating became disordered. These medications quiet appetite in a way that can be freeing for some people and destabilizing for others.

And I ask a question that surprises people: what are you hoping this changes about your life? Sometimes the honest answer reveals that the real goal isn't a number on a scale at all. That's useful. It tells me whether a peptide protocol is even the right tool, or whether we should be talking about something else entirely.

I also pay attention to context that gets overlooked. The healthy weight thresholds are lower than the older Western cutoffs. A WHO expert consultation published in the Lancet in 2004 recommended lower BMI action points for Asian populations, because metabolic risk tends to appear at a lower body weight. STEP 6, published in Lancet Diabetes and Endocrinology, studied semaglutide specifically in an East-Asian population and is one of the few large trials I can point to for patients who look more like the people in my waiting room. I bring this up because a BMI that seems modest by an old chart may still carry real risk.

The upside and the downside

I try to give both sides in the same breath, because that's the only fair way to do it.

The upside is genuine. Beyond weight, many patients tell me they feel a kind of quiet around food they haven't felt in years. The constant background noise of wanting to eat gets softer. For people who have fought that noise their whole lives, that alone can feel like relief. And the metabolic benefits, better blood sugar control in particular, show up clearly in the trial data. SURPASS-2, another New England Journal of Medicine study, showed strong blood sugar improvements with tirzepatide.

Now the downside, because you deserve it plainly. The most common side effects are digestive: nausea, constipation, sometimes vomiting, especially in the early weeks and after any increase. For most people these ease over time. For some they don't, and we have to make a decision about whether to continue. I've written more about the side effects nobody warns you about, and I'd rather you read that with clear eyes than discover it the hard way.

There's also the weight you can lose that you don't want to lose. Some of what comes off during rapid weight loss is muscle, not just fat. Age already works against us here. Larsson and colleagues described in Physiological Reviews how muscle mass declines with age, a process called sarcopenia. Layer aggressive weight loss on top of that and the muscle question becomes real. This is why I talk about protein intake and resistance training from the start, not as an afterthought.

And there's the maintenance reality I mentioned. Your body defends its old weight. Rosenbaum and Leibel described this in the International Journal of Obesity: after weight loss, the body burns slightly fewer calories than you'd predict, a phenomenon called adaptive thermogenesis. It's a headwind. Not an impossible one, but a real one. Lundgren and colleagues showed in the New England Journal of Medicine that combining exercise with a GLP-1 medication helped people hold onto their results better than the medication alone. That finding shapes how I counsel almost everyone.

Who I think should wait, or not start at all

Not everyone who wants a peptide protocol is a good candidate, and part of my job is saying so kindly.

I'm cautious with anyone who is pregnant, trying to become pregnant, or breastfeeding. I'm cautious with a history of certain thyroid cancers or pancreatitis. I'm cautious when someone has an active eating disorder or a recent history of one, because a medication that suppresses appetite can feed the wrong pattern. And I'm cautious when I sense that the expectation is a fast, effortless transformation with no intention of changing anything else. That mindset tends to end in disappointment and often in weight regain.

I also pause when someone wants to start based purely on how they look rather than any measure of health, particularly if their weight is already in a healthy range. Losing weight you don't need to lose carries risk without much benefit.

None of these are permanent doors closing. Some are timing questions. Some are "let's address this other thing first" questions. But I won't hand someone a protocol just because they asked for one. That's not care.

I'll add one more caution that has nothing to do with your body and everything to do with product quality. Peptides are proteins, and proteins are fragile. Research has shown that physical stress damages them: Zapadka and colleagues, writing in Interface Focus, described how agitation drives peptide aggregation, and Jain and colleagues showed in Scientific Reports that freeze-thaw cycles trigger protein aggregation too. What that means for you is that how a product is made, shipped, and stored matters as much as what's on the label. A poorly handled vial isn't the medication that was studied in those trials.

What I tell my patients

I tell you that this is a tool, not a verdict on your willpower. If you've struggled with weight, that struggle was never a character flaw. It was biology working against you, and these medications happen to speak the same language your biology does.

I tell you to go slow and to expect the early weeks to be the roughest. The nausea, if it comes, usually settles. I tell you not to chase the fastest possible loss, because the muscle you keep and the habits you build will matter more in year two than how quickly the scale moves in month one.

I tell you that a plateau is coming and it isn't a sign you did something wrong. In the two-year STEP 5 trial of semaglutide, published in Nature Medicine by Garvey and colleagues, the weight loss was steep at first and then flattened out at around week 60, and it held there for the rest of the study. So the plateau is a known part of the curve, not a personal failing. When you hit it, we adjust the plan, we don't panic.

I tell you to protect your muscle actively: eat enough protein, keep moving, lift something heavy a few times a week if your body allows it. And I tell you the truth about stopping, so you can make that decision with real information rather than surprise.

Most of all, I tell you that I want to hear from you between visits. The people who do best are the ones who tell me early when something feels off, not the ones who tough it out silently. If you want to understand the safety picture before you commit, I've written about whether GLP-1 peptides are safe for first-time users, and it's a good companion to this conversation.

When to talk to someone

Everything I've written here is education, not a prescription for you specifically. The screening I described only works face to face, with your history, your labs, and your medication list in front of a provider who can examine you.

So before you start anything, sit down with a qualified medical provider and have the version of this conversation that's built around you. Ask about your specific risks. Bring your full medication list. Be honest about your history with food and your reasons for wanting this. A good provider will welcome all of it.

If something changes once you've started, severe or persistent vomiting, signs of dehydration, intense abdominal pain, or anything that frightens you, don't wait for your next appointment. Reach out. If you're starting a Peptaralabs protocol, our team answers questions on WhatsApp, and I'd rather you ask early than worry alone.

Sources

Jastreboff et al., 2022, New England Journal of Medicine. SURMOUNT-1, tirzepatide for obesity.

Wilding et al., 2021, New England Journal of Medicine 384(11):989-1002. STEP 1, semaglutide for obesity.

Wilding et al., 2022, Diabetes, Obesity and Metabolism. STEP 1 extension, weight regain after stopping semaglutide.

Aronne et al., 2024, JAMA. SURMOUNT-4, weight regain after withdrawing tirzepatide.

Frias et al., 2021, New England Journal of Medicine 385(6):503-515. SURPASS-2, tirzepatide, blood sugar improvement in type 2 diabetes.

Rosenbaum and Leibel, 2010, International Journal of Obesity 34(Suppl 1):S47-S55. Adaptive thermogenesis in humans after weight loss.

Lundgren et al., 2021, New England Journal of Medicine 384(18):1719-1730. Exercise, liraglutide, or both for weight-loss maintenance.

Garvey et al., 2022, Nature Medicine 28:2083-2091. STEP 5, two-year semaglutide, weight loss plateaued around week 60.

Kadowaki et al., 2022, Lancet Diabetes and Endocrinology 10(3):193-206. STEP 6, semaglutide in an East-Asian population.

Calvarysky et al., 2024, Drug Safety 47(5):439-451. GLP-1 drug-drug interactions and delayed gastric emptying.

Larsson et al., 2019, Physiological Reviews 99(1):427-511. Sarcopenia, age-related muscle loss.

Zapadka et al., 2017, Interface Focus 7(6):20170030. Agitation drives peptide aggregation.

Jain et al., 2021, Scientific Reports 11:11332. Freeze-thaw triggers protein aggregation.

This article is for educational purposes. It does not replace personal medical evaluation. Individual responses to peptides vary based on factors a physician needs to assess in person. If you're considering starting a peptide protocol, consult a qualified medical provider about your specific situation.

Chat with us